The Global Impact of the Gynecologic Cancer InterGroup in Enhancing Clinical Trials in Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 746-749 ◽  
Author(s):  
Monica Bacon ◽  
Henry Kitchener ◽  
Gavin C.E. Stuart ◽  
Jan B. Vermorken
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Consensus Conference ◽  
International Forum ◽  
Gynecologic Cancers ◽  
International Differences ◽  
Global Impact ◽  
Multiple Issues

The Gynecologic Cancer InterGroup (GCIG) has developed from a small network of ovarian cancer researchers to a large international forum addressing multiple issues related to research in gynecologic cancers. Member groups of the GCIG have collaboratively conducted pivotal clinical trials in cancers of the ovary, endometrium, and cervix. The participation of operational and statistical personnel from the GCIG member groups has facilitated a collegial approach to international differences and restrictions.One of the powerful initiatives of the GCIG is the facilitation of the Ovarian Cancer Consensus Conference every few years. The 4th Ovarian Cancer Consensus Conference was held in Vancouver, Canada, in June 2010, and the resulting publications (herein) provide an invaluable resource to researchers in the field of gynecologic oncology.

Clinical Trials in Recurrent Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Friedlander ◽  
Edward Trimble ◽  
Anna Tinker ◽  
David Alberts ◽  
Elisabeth Avall-Lundqvist ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Cancer ◽  
Recurrent Ovarian Cancer ◽  
Consensus Conference ◽  
Ca 125 ◽  
Therapeutic Approaches ◽  
Cooperative Research ◽  
International Consensus

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

scholarly journals Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

2017 ◽  
Vol 28 ◽  
pp. viii30-viii35 ◽  
Author(s):  
M.A. Bookman ◽  
A. Okamoto ◽  
G. Stuart ◽  
N. Yanaihara ◽  
D. Aoki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Unmet Needs ◽  
Gynecologic Cancer ◽  
Consensus Conference

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

2011 ◽  
Vol 21 (4) ◽  
pp. 750-755 ◽  
Author(s):  
Gavin C.E. Stuart ◽  
Henry Kitchener ◽  
Monica Bacon ◽  
Andreas duBois ◽  
Michael Friedlander ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Consensus Statement ◽  
Gynecologic Cancer ◽  
Consensus Conference

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference.

scholarly journals The Role of Operative Laparoscopy in Gynecologic Oncology

1996 ◽  
Vol 2 (4) ◽  
pp. 185-188 ◽  
Author(s):  
E. M. Hartenbach ◽  
J. M. Fowler
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Paraaortic Lymph Node ◽  
Node Dissection ◽  
Operative Laparoscopy ◽  
Pelvic Malignancies ◽  
Potential Applications ◽  
Paraaortic Lymph Node Dissection

The potential applications of operative laparoscopy have expanded with improvements in technology and instrumentation. With newly developed techniques to complete both pelvic and paraaortic lymph node dissection, the use of the laparoscope has increased in patients with pelvic malignancies. Gynecologic oncologists are currently incorporating the techniques of operative laparoscopy in the management of patients with cervical, endometrial, and ovarian cancer. Multicenter prospective clinical trials are necessary to further define the role of laparoscopy in gynecologic oncology.

Gynecologic Oncologist Perspective About ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

2017 ◽  
Vol 27 (4) ◽  
pp. 826-831 ◽  
Author(s):  
Polat Dursun ◽  
Ali Ayhan
Keyword(s):  
Endometrial Cancer ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Daily Practice ◽  
Consensus Conference ◽  
Point Of View ◽  
Great Effort ◽  
Care Providers ◽  
Nccn Guidelines ◽  
Huge Impact

AbstractESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer was simultaneously published in 3 prestigious journals and is sure to have a huge impact on the clinical practice of gynecologic oncology community and other gynecologic cancer care providers.It is a tremendous report representative of great effort. Hovewer, as practicing gynecologic oncologists, endometrial carcinoma is the most common clinical entity encountered in our routine daily practice; as such, we find some of the report confusing and object to some of its findings, as detailed in this brief report.We also attempted to summarize the differences between the well-known NCCN guidelines and the ESMO-ESGO-ESTRO Consensus Conference guidelines and try to give the point of view of gynecologic oncologic perspective. It is obvious that differences in the management of endometrial carcinomas will continue to be debated by the scientific community.

scholarly journals Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 903
Author(s):  
Daniela Califano ◽  
Daniela Russo ◽  
Giosuè Scognamiglio ◽  
Nunzia Simona Losito ◽  
Anna Spina ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Clinical Data ◽  
Gynecologic Cancer ◽  
Years Of Experience ◽  
Web Based ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Embedded Blocks ◽  
Formalin Fixed

Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes.

Sign in / Sign up

Export Citation Format

Share Document